Tocilizumab for severe hantavirus pulmonary syndrome: five treated patients, a signal only

Design

Descriptive case series under a monitored emergency-use framework, single hospital, within a larger pre-post study

Population

10 eligible patients with severe hantavirus pulmonary syndrome (5 treated, 5 untreated)

Primary outcome

Survival to ICU discharge

Effect

4 of 5 treated survived; 0 of 5 eligible untreated survived

In a single Argentine hospital, patients with laboratory-confirmed severe hantavirus pulmonary syndrome needing intensive care could receive a single intravenous dose of tocilizumab 8 mg/kg (maximum 800 mg) within 24 hours of ICU admission or assessment, on top of supportive care, under a monitored emergency-use framework. Between June 2024 and May 2026, 13 patients were evaluated, and 10 met criteria.

Five received tocilizumab and five did not. Of the untreated five, two presented in refractory shock and three could not be treated because the drug was unavailable. Four of five treated patients survived to ICU discharge; the fifth died after rapid progression to refractory shock. All five untreated patients died.

The groups were not randomised, and the untreated patients differed in an important way: some were too ill to receive the drug in time. Five patients per group cannot separate a drug effect from earlier presentation or from timing and availability. The authors themselves call for further evaluation within monitored frameworks and collaborative randomised studies. No immunomodulatory drug has been shown effective for this disease.

• Do not use tocilizumab for hantavirus pulmonary syndrome outside a monitored protocol on this evidence.
• Provide early intensive care and supportive management; this is the established approach.
• Consider hantavirus in febrile patients with rapidly worsening respiratory failure and a rodent exposure history.
• Contact your regional infectious disease or public health unit when a case is suspected.

Why it matters

It raises IL-6 inhibition as a target for a disease with no proven specific therapy, and shows what a proper trial would need to control for.

Don't overread it

A five-versus-five descriptive series without randomisation cannot show that tocilizumab saves lives; this report was published in June, not this week.

The statistics, in plain English

Four of five versus zero of five sounds striking, but with groups this small a difference of that size could arise from who was able to receive the drug in time. No confidence interval or adjustment was possible, and the untreated group included patients too ill to be treated.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.